WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. (Q53345813)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

0 references

author name string

Anri Saitoh

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Miwako Narita

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Norihiro Watanabe

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Nozomi Tochiki

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Akie Yamahira

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Takeshi Nakamura

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Masami Kaji

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Masayoshi Masuko

8

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Tatsuo Furukawa

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Ken Toba

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Ichiro Fuse

11

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Yoshifusa Aizawa

12

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Masuhiro Takahashi

13

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

publication date

27 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

28

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

219-230

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

https://scigraph.springernature.com/pub.10.1007/s12032-010-9425-3

0 references

Dendritic cell-based cancer vaccination: quo vadis?

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

WT1 peptide vaccine for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Regulatory T cells in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

FOXP3 expression and overall survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Zinc is essential for binding of p56(lck) to CD4 and CD8alpha

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS12032-010-9425-3

21 January 2018

Establishment of a new cell line with the characteristics of a multipotential progenitor from a patient with chronic myelogenous leukemia in early erythroblastic crisis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antigen-specific Treg impair CD8(+) T-cell priming by blocking early T-cell expansion.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increase of regulatory T cells in the peripheral blood of cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme

1 reference

https://pubmed.ncbi.nlm.nih.gov/20107936

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12032-010-9425-3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/20107936

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53345813&oldid=1404991340"